Original Research

Published on 12 Jul 2024

The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China

in Drugs Outcomes Research and Policies

Lu Li
Shilei Yang
Fengqi Fang
Li Tian
Ying He
Jia Li
Yanwei Chen
Deshi Dong

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1382120

1,369 views

Original Research

Published on 12 Jul 2024

Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatin versus sintilimab plus gemcitabine and cisplatin or carboplatin for the first-line treatment of local advanced or metastatic squamous NSCLC in Chinese mainland

in Drugs Outcomes Research and Policies

Xiaoting Liu
Xiao-xue Liu
Wenqing Shao
Yi Zhou
Jing Zhang
Cuirong Zhao
Chengwu Shen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1356725

1,039 views

Brief Research Report

Published on 12 Jul 2024

Is it time to recommend AUC-based vancomycin therapeutic drug monitoring only? A cross-sectional survey in China

in Drugs Outcomes Research and Policies

Jieqiong Liu
Xuan Zhang
Gang Liang
Jianping Zhu
Yi Yang
Ying Zheng
Yun Han
Lingyan Yu
Yuhua Zhao
Zhenwei Yu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1370040

1,017 views

Original Research

Published on 11 Jul 2024

Cost-effectiveness of utidelone and capecitabine versus monotherapy in anthracycline- and taxane-refractory metastatic breast cancer

in Drugs Outcomes Research and Policies

Mulan Chen
Heng Zhang
Xiaoyan He
Yingtao Lin

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1303808

803 views

Original Research

Published on 10 Jul 2024

Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018–2023

in Drugs Outcomes Research and Policies

Jinger Lin
Xiangqi Chen
Min Luo
Qianwei Zhuo
Haosong Zhang
Nuo Chen
Yunqian Zhuo
Yue Han

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1420478

2,143 views

Original Research

Published on 10 Jul 2024

Evaluating drug withdrawal syndrome risks through food and drug administration adverse event reporting system: a comprehensive disproportionality analysis

in Drugs Outcomes Research and Policies

Zheng Zhang
Qianzhi Yang
Minghao Chen
Wah Yang
Yuping Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1385651

2,183 views

Original Research

Published on 08 Jul 2024

Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events

in Drugs Outcomes Research and Policies

Long He
Qiuyu Li
Yongfeng Yang
Jiahao Li
Wei Luo
Yilan Huang
Xiaoyan Zhong

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1416985

3,699 views
1 citation

Original Research

Published on 05 Jul 2024

A point prevalence survey and monitoring indicator research on the second batch of national key monitoring and rational use drugs

in Drugs Outcomes Research and Policies

Li Tang
Hongmei Liu
Shasha Wu
Jing Liu
Xiaoyu Jiang
Yuanyuan Fu
Na Tao
Yong He

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1416010

686 views

Original Research

Published on 02 Jul 2024

Patient preferences for generic substitution policies: a discrete choice experiment in China

in Drugs Outcomes Research and Policies

Lingli Zhang
Dashuang Li
Xin Li
Jianzhou Yan

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1400156

1,090 views

Original Research

Published on 28 Jun 2024

Development and validation of the BMQ-AIR©: a screening tool for assessing patients’ treatment beliefs about switching to anti-inflammatory reliever (AIR) therapy

in Drugs Outcomes Research and Policies

Holly Foot
Amy Hai Yan Chan
Rob Horne

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1351851

904 views

Original Research

Published on 27 Jun 2024

Does China’s national volume-based drug procurement policy promote or hinder pharmaceutical innovation?

in Drugs Outcomes Research and Policies

Xiujuan Li
Jiachun Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1392239

2,594 views
2 citations

Original Research

Published on 26 Jun 2024

Physicians’ perceptions and awareness of adverse effects of proton pump inhibitors and impact on prescribing patterns

in Drugs Outcomes Research and Policies

Abdelmoneim Awad
Abdulaziz Al-Tunaib
Sarah Al-Saraf

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1383698

1,221 views
1 citation

Original Research

Published on 24 Jun 2024

Unraveling elements of value-based pricing from a pharmaceutical industry’s perspective: a scoping review

in Drugs Outcomes Research and Policies

Aniek Dane
Carin Uyl-de Groot
Hugo van der Kuy

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1298923

1,998 views

Original Research

Published on 20 Jun 2024

Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer

in Drugs Outcomes Research and Policies

Gengwei Huo
Ying Song
Wei Liu
Hua Guo
Peng Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1391896

1,673 views

Original Research

Published on 19 Jun 2024

Implementation of risk-based lipid-lowering therapies in older (age ≥ 65 years) and very-old adults (age ≥ 75 years) with ischemic heart disease in the greater Salzburg region

in Drugs Outcomes Research and Policies

Kristen Kopp
Lukas J. Motloch
Bernhard Wernly
Alexander E. Berezin
Victoria Maringgele
Anna Dieplinger
Uta C. Hoppe
Michael Lichtenauer

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1357334

1,026 views

Original Research

Published on 19 Jun 2024

Understanding patient demand for and use of antibiotics for upper respiratory tract infection: A qualitative application of the Necessity-Concerns Framework in Saudi Arabia

in Drugs Outcomes Research and Policies

Nouf Almeshal
Holly Foot
Amy Louise Clarke
Amy Hai Yan Chan
Rob Horne

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1399698

2,256 views

Navigation group

Articles

The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China

Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatin versus sintilimab plus gemcitabine and cisplatin or carboplatin for the first-line treatment of local advanced or metastatic squamous NSCLC in Chinese mainland

Is it time to recommend AUC-based vancomycin therapeutic drug monitoring only? A cross-sectional survey in China

Cost-effectiveness of utidelone and capecitabine versus monotherapy in anthracycline- and taxane-refractory metastatic breast cancer

Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018–2023

Evaluating drug withdrawal syndrome risks through food and drug administration adverse event reporting system: a comprehensive disproportionality analysis

Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events

A point prevalence survey and monitoring indicator research on the second batch of national key monitoring and rational use drugs

Patient preferences for generic substitution policies: a discrete choice experiment in China

Development and validation of the BMQ-AIR©: a screening tool for assessing patients’ treatment beliefs about switching to anti-inflammatory reliever (AIR) therapy

Does China’s national volume-based drug procurement policy promote or hinder pharmaceutical innovation?

Physicians’ perceptions and awareness of adverse effects of proton pump inhibitors and impact on prescribing patterns

Unraveling elements of value-based pricing from a pharmaceutical industry’s perspective: a scoping review

Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer

Implementation of risk-based lipid-lowering therapies in older (age ≥ 65 years) and very-old adults (age ≥ 75 years) with ischemic heart disease in the greater Salzburg region

Understanding patient demand for and use of antibiotics for upper respiratory tract infection: A qualitative application of the Necessity-Concerns Framework in Saudi Arabia